Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-293-7 | CAS number: 56-86-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Neurotoxicity
Administrative data
- Endpoint:
- neurotoxicity: sub-chronic oral
- Type of information:
- other: SIDS
- Adequacy of study:
- other information
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- Effects of dietary supplementation of monosodium glutamate on infant monkeys, weanling rats, and suckling mice
- Author:
- Wen C-P, Hayes KC and Gershoff SN
- Year:
- 1 973
- Bibliographic source:
- The American Journal of Clinical Nutrition 26: 803-813.
- Reference Type:
- publication
- Title:
- SIDS for L-Glutamic acid
- Author:
- OECD
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
Test material
- Specific details on test material used for the study:
- Test material equivalent to submission substance identity:
yes
Test animals
- Species:
- rat
- Strain:
- other: Charles River CD
- Sex:
- male
Administration / exposure
- Route of administration:
- oral: feed
- Duration of treatment / exposure:
- 5 weeks
- Frequency of treatment:
- daily
Doses / concentrations
- Dose / conc.:
- 174 000 mg/kg diet
- Remarks:
- nominal in diet
- No. of animals per sex per dose:
- 6
- Control animals:
- yes
- Details on study design:
- [group 1] 100 g basal diet plus 20 g glucose;
[group 2] 100 g basal diet plus 20 g MSG;
[group 3] 100 g basal diet plus 40 g MSG;
[group 4] 100 g basal diet plus 17.4 g L-glutamic acid, the amount of glutamic acid in 20 g MSG;
[group 5] 100 g basal diet plus 1.5 g Na2S04, 1.5 g Na2CO3, 2 g NaHCO3, 2 g NaCl, 3 g glycine, 2.5 g L-alanine, 2.5 g L-glutamic acid, 1.3 g ammonium citrate, and 2.3 g L-serine (These supplements provided approximately the same quantity of sodium and nonessential amino acid nitrogen found in 20 g MSG).
Examinations
- Observations and clinical examinations performed and frequency:
- Weekly body weights, daily water consumption during the last 2 weeks, and the pH of the pooled urine samples from each group were recorded.After a 5-week period, the rats were fasted overnight and then fed ad libitum for 90 minutes prior to decapitation. Postprandial blood samples were collected from the neck for plasma glutamate determination.Organs of interest were weighed and brains and testes were fixed in 10% buffered formalin for histologic examination of hematoxylin- and eosin-stained sections. Serial frozen sections of formalin-fixed brain were also stained with the Fink and Heimer silver stain for degenerating axons.
Results and discussion
Results of examinations
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Average terminal body and brain weights were less than those of the control groups.
- Description (incidence and severity):
- Food intake was decreased in the four treatment groups.
- Description (incidence and severity):
- Rats fed free glutamic acid in group 4 had lower plasma glutamate than rats fed diets containing the same amount of glutamic acid as MSG.
- Neuropathological findings:
- no effects observed
- Description (incidence and severity):
- No specific endocrine or neurological defects were seen.
- Description (incidence and severity):
- The weights of adrenal glands and testes, expressed per 100 g body wt, were increased by supplements of either MSG or L-glutamic acid.The group fed L-glutamic acid consumed more water than the control group fed a similar amount of glucose.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 174 000 mg/kg diet
Applicant's summary and conclusion
- Conclusions:
- L-glutamic acid did not show specific endocrine or neurological defects.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.